o	A trial in advanced cervical cancer will be initiated in 4Q2023 with potential
registrational intent 

o	Dose-finding Phase 1/2a trial in 1st line patients with advanced head and neck
squamous cell carcinoma to begin in 1H2023

o	Evaluate and plan for expansion into HPV16-positive anal, penile, vaginal and
vulvar cancer

o	Expanding clinical program into PD-L1 negative tumors

                                                  ---

Management will host a webcast today at 11 a.m. CET (in Norwegian) and 4 p.m.
CET / 10 a.m. ET (in English) to discuss the development plan 

Company selected to present at the 41st Annual J.P. Morgan Healthcare Conference
in January 2023


Oslo, Norway, December 20, 2022 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced an expanded clinical
development plan for VB10.16, the Company's wholly-owned cancer vaccine, for the
treatment of HPV16-positive cancers with high unmet need. Nykode Management will
host a webcast today, December 20, 2022, to discuss the development plan at 11
a.m. CET (in Norwegian) and 4 p.m. CET/10 a.m. ET (in English).

VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to
treat HPV16-induced malignancies. The drug candidate has reported interim data
from VB-C-02, a Phase 2 trial in heavily pre-treated cervical cancer patients.
The analysis demonstrated a favorable safety profile, with responses observed in
both PD-L1 positive and negative patients (ORR 27% and 17%, respectively). The
vaccine-induced significant HPV16-specific T cell responses that were associated
with clinical responses.

"Today we announce our expanded VB10.16 development plan underlining our
confidence in the product candidate's potential to treat a broad group of
HPV-related cancer patients with significant unmet need. These indications
constitute a large potential market opportunity for Nykode. Our potential
registrational trial strategy disclosed today in advanced cervical cancer could
provide a fast path to making VB10.16 available to patients. I am excited by our
ambitious VB10.16 development plans and our recently signed agreements
supporting the development. We remain committed to taking full advantage of the
potential of VB10.16 and Nykode's technology platform," said Michael Engsig,
Chief Executive Officer of Nykode Therapeutics.  

Klaus Edvardsen, Chief Development Officer of Nykode Therapeutics, stated: "The
interim results from our C-02 Phase 2 trial show the ability of VB10.16 to
improve clinical outcomes in heavily pre-treated patients with advanced cervical
cancer. Our next trial in advanced cervical cancer will focus on patients who
failed first line treatment including checkpoint inhibitor treatment. In this
patient group with limited treatment options and a significant unmet need, we
aim for a potential registrational trial."


Expanded VB10.16 Clinical Development Plan 

Cervical Cancer

Nykode is planning to conduct a single arm trial, VB-C-04, with potential
registrational intent in 2nd line immune checkpoint inhibitor refractory
advanced cervical cancer patients. The trial will be conducted in the United
States and initiated in the fourth quarter of 2023.

Head and Neck Cancer 

Nykode is planning to conduct an open-label, dose-finding, single arm Phase
1b/2a trial of VB10.16 in combination with pembrolizumab in patients with first
line HPV16-postive, recurrent or metastatic squamous cell head and neck cancer
as described in Nykode's announcement on December 6, 2022:
https://nykode.com/media/news-and-announcements/. The trial, VB-C-03, will
evaluate the overall response rate, safety, tolerability, and antigen specific
immune response of the combination therapies. Nykode expects to enroll patients
in Europe during the first half of 2023. 

Basket Trial

Nykode expects to collaborate on an investigator-initiated basket trial to
evaluate VB10.16 in combination with a PD-L1 inhibitor in patients diagnosed
with HPV16-positive anal, penile, vaginal and/or vulvar cancer who are no longer
eligible for curative treatments. The trial is expected to enroll patients with
both PD-L1 positive and PD-L1 negative tumors.

Nykode will continue to study VB10.16 in patients with PD-L1 negative tumors to
investigate VB10.16's potential for a dedicated trial in such a patient
population. 


Webcast

Investors and analysts are invited to join a webcast presentation of the VB10.16
development plan conducted by Michael Engsig, Chief Executive Officer, and Klaus
Edvardsen, Chief Development Officer, today, December 20, 2022 at:

11 a.m. CET / 5 a.m. ET which will be conducted in Norwegian

4 p.m. CET / 10 a.m. ET which will be conducted in English

The slide presentation and live and archived webcast can be accessed in the
Investors section of the Company's website at
https://nykode.com/investors/financial-reports-and-presentations.


41st Annual J.P. Morgan Healthcare Conference

Nykode Management will present at the 41st Annual J.P. Morgan Healthcare
Conference, taking place January 9-12, 2023, in San Francisco, California. 


About VB10.16
VB10.16 is a potentially first-in-class off-the-shelf therapeutic cancer vaccine
candidate in development for the treatment of human papillomavirus type 16
(HPV16)-positive cancers. The cancer vaccine is designed based on Nykode's
VaccibodyTM technology platform of targeting antigens to antigen presenting
cells. VB10.16 has reported positive interim data from a Phase 2 trial in
heavily pre-treated cervical cancer patients (NCT04405349). The analysis
demonstrated a favorable safety profile, with responses observed in both PD-L1
positive and negative patients (ORR 27% and 17%, respectively). The
vaccine-induced significant HPV16-specific T cell responses were associated with
clinical responses. The candidate has also demonstrated favorable clinical data
in a Phase 1/2a study in pre-cancerous HPV16-induced high grade cervical
intraepithelial neoplasia (HSIL